Idera Pharmaceuticals, Inc. Presents Data in Preclinical Models of Lymphoma on IMO-4200, a Dual Agonist of TLRs 7 and 8, at the American Society of Hematology

Published: Dec 14, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals (Nasdaq: IDRA) today announced that it presented new data showing that IMO-4200, a dual agonist of Toll-like receptor (TLR) 7 and TLR8, in combination with approved cancer treatments increased antitumor activity in preclinical models of lymphoma. The presentation by Idera scientists, entitled “IMO-4200, a novel TLR7 and TLR8 dual agonist, enhances antitumor effect of ofatumumab, rituximab and cytotoxics in preclinical models of hematological malignancies”, abstract number 3724, was made at the 53rd annual meeting of the American Society for Hematology being held in San Diego, California December 11-13, 2011.

Back to news